Last reviewed · How we verify
NCT06088134
Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)
trial in Clear Cell Renal Cell Carcinoma in 800 participants. Currently enrolling.
1 June 2025
Quick facts
| Lead sponsor | Mingzhao Xiao |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 1 September 2022 |
| Primary completion | 1 June 2025 |
| Estimated completion | 1 August 2025 |
| Sites | 1 location across China |
Conditions studied
- Clear Cell Renal Cell Carcinoma — all drugs for Clear Cell Renal Cell Carcinoma →
- Prognostic Cancer Model — all drugs for Prognostic Cancer Model →
- Recurrent Renal Cell Cancer — all drugs for Recurrent Renal Cell Cancer →
Sponsor
Mingzhao Xiao
Who can join
Eligibility, any sex, with Clear Cell Renal Cell Carcinoma or Prognostic Cancer Model. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aims to preoperatively predict DFS of patients with localised ccRCC using a deep learning prognostic model based on enhanced contrast CT images, validate it's predictive ability in multicentre data and compare it's predictive ability with traditional models.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Three-dimensional deep learning model complements existing models for preoperative disease-free survival prediction in localized clear cell renal cell carcinoma: a multicenter retrospective cohort study.
Xv Y, Wei Z, Jiang Q, Zhang X, et al · · 2024 · cited 3× · PMID 38896853 · DOI 10.1097/js9.0000000000001808
Verify or expand the search:
- PubMed search for NCT06088134
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Clear Cell Renal Cell Carcinoma
Currently open trials in the same condition.
- NCT06863311 — Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear C · Phase 2 · recruiting
- NCT07227415 — Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Antica · Phase 1, PHASE2 · recruiting
- NCT07187778 — Phase II Trial of Single Agent Belzutifan or Pembrolizumab Versus Combination as Neoadjuvant Therapy in Clear Cell Renal · Phase 2 · recruiting
- NCT07389629 — Iparomlimab and Tuvonralimab (QL1706) Combination With Lenvatinib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
- NCT06805825 — A Study of the c-Kit Specific Antibody-Drug Conjugate NN3201 for Advanced and/or Metastatic Solid Tumors Known to Expres · Phase 1 · recruiting
Other Mingzhao Xiao trials
Trials by the same sponsor.
- NCT06993779 — Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Upper Tract Urothelial C · active not recruiting
- NCT06389019 — Whole-slide Image and CT Radiomics Based Deep Learning System for Prognostication Prediction in Bladder Cancer · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06088134 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Mingzhao Xiao
- Last refreshed: 31 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06088134.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing